Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 33 | 2022 | 791 | 8.150 |
Why?
|
| Vitamin D | 9 | 2018 | 516 | 3.120 |
Why?
|
| Anti-Retroviral Agents | 7 | 2021 | 53 | 2.100 |
Why?
|
| Anti-HIV Agents | 9 | 2020 | 135 | 1.890 |
Why?
|
| Cardiovascular Diseases | 8 | 2017 | 940 | 1.810 |
Why?
|
| Dietary Supplements | 4 | 2018 | 332 | 1.600 |
Why?
|
| Vitamin D Deficiency | 5 | 2017 | 292 | 1.580 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2016 | 212 | 1.440 |
Why?
|
| HIV-1 | 5 | 2018 | 177 | 1.420 |
Why?
|
| Inflammation | 7 | 2021 | 1030 | 1.390 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2019 | 92 | 1.210 |
Why?
|
| CD4 Lymphocyte Count | 8 | 2021 | 98 | 1.080 |
Why?
|
| Bone Density | 3 | 2017 | 159 | 1.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2018 | 73 | 0.960 |
Why?
|
| Carotid Intima-Media Thickness | 5 | 2017 | 54 | 0.910 |
Why?
|
| Child | 15 | 2021 | 6405 | 0.890 |
Why?
|
| Young Adult | 17 | 2021 | 5717 | 0.890 |
Why?
|
| Adolescent | 18 | 2019 | 8912 | 0.830 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2019 | 35 | 0.820 |
Why?
|
| Biomarkers | 9 | 2021 | 1593 | 0.820 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2021 | 5 | 0.760 |
Why?
|
| Lymphocyte Activation | 3 | 2018 | 397 | 0.750 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 34 | 0.740 |
Why?
|
| Interleukin-6 | 2 | 2020 | 330 | 0.740 |
Why?
|
| Feces | 1 | 2021 | 88 | 0.730 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2020 | 12 | 0.700 |
Why?
|
| Fibroblast Growth Factors | 1 | 2020 | 51 | 0.700 |
Why?
|
| Biological Products | 1 | 2021 | 78 | 0.690 |
Why?
|
| Weight Gain | 1 | 2020 | 135 | 0.660 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 234 | 0.650 |
Why?
|
| Antiviral Agents | 1 | 2021 | 211 | 0.640 |
Why?
|
| Risk Factors | 11 | 2020 | 5731 | 0.640 |
Why?
|
| Humans | 36 | 2022 | 68618 | 0.610 |
Why?
|
| Immunomodulation | 1 | 2018 | 35 | 0.600 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 69 | 0.590 |
Why?
|
| Carotid Arteries | 1 | 2017 | 110 | 0.580 |
Why?
|
| Vascular Stiffness | 1 | 2017 | 31 | 0.570 |
Why?
|
| Neurocognitive Disorders | 1 | 2017 | 23 | 0.570 |
Why?
|
| Adult | 18 | 2021 | 21403 | 0.560 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2017 | 58 | 0.550 |
Why?
|
| Immunity | 1 | 2017 | 67 | 0.550 |
Why?
|
| Amino Acids | 1 | 2017 | 131 | 0.550 |
Why?
|
| Double-Blind Method | 6 | 2017 | 1738 | 0.550 |
Why?
|
| Bone Diseases | 1 | 2016 | 20 | 0.540 |
Why?
|
| Bone Development | 1 | 2016 | 37 | 0.540 |
Why?
|
| Female | 22 | 2021 | 38074 | 0.530 |
Why?
|
| Cholecalciferol | 1 | 2017 | 143 | 0.530 |
Why?
|
| Cytokines | 3 | 2019 | 866 | 0.530 |
Why?
|
| Serpins | 1 | 2016 | 205 | 0.480 |
Why?
|
| Cross-Sectional Studies | 6 | 2017 | 2279 | 0.480 |
Why?
|
| Dyslipidemias | 1 | 2015 | 98 | 0.480 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2014 | 21 | 0.480 |
Why?
|
| Male | 19 | 2021 | 37321 | 0.470 |
Why?
|
| Fluorobenzenes | 1 | 2014 | 10 | 0.470 |
Why?
|
| Vasculitis | 1 | 2014 | 33 | 0.460 |
Why?
|
| Child, Preschool | 7 | 2021 | 3187 | 0.460 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 176 | 0.450 |
Why?
|
| Sulfonamides | 1 | 2014 | 141 | 0.430 |
Why?
|
| Pyrimidines | 1 | 2014 | 178 | 0.420 |
Why?
|
| Viral Load | 3 | 2018 | 127 | 0.420 |
Why?
|
| Feeding Behavior | 1 | 2014 | 224 | 0.420 |
Why?
|
| Infant | 6 | 2019 | 2891 | 0.390 |
Why?
|
| Treatment Outcome | 6 | 2021 | 7029 | 0.340 |
Why?
|
| Rosuvastatin Calcium | 3 | 2016 | 5 | 0.290 |
Why?
|
| HIV | 3 | 2019 | 56 | 0.280 |
Why?
|
| Benzoxazines | 2 | 2017 | 20 | 0.280 |
Why?
|
| Influenza Vaccines | 2 | 2019 | 56 | 0.270 |
Why?
|
| Osteoporosis | 2 | 2016 | 88 | 0.250 |
Why?
|
| Pregnancy | 4 | 2019 | 2334 | 0.230 |
Why?
|
| Smoking Cessation | 2 | 2022 | 1034 | 0.230 |
Why?
|
| T-Lymphocytes | 2 | 2018 | 597 | 0.220 |
Why?
|
| Comorbidity | 2 | 2016 | 1426 | 0.200 |
Why?
|
| Adipose Tissue | 2 | 2020 | 221 | 0.200 |
Why?
|
| Prospective Studies | 3 | 2014 | 3705 | 0.200 |
Why?
|
| Influenza, Human | 2 | 2019 | 79 | 0.180 |
Why?
|
| Pulse Wave Analysis | 2 | 2017 | 9 | 0.180 |
Why?
|
| Cyclopropanes | 2 | 2017 | 10 | 0.180 |
Why?
|
| Oxazines | 1 | 2020 | 10 | 0.180 |
Why?
|
| Alkynes | 2 | 2017 | 12 | 0.180 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2020 | 11 | 0.180 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 180 | 0.180 |
Why?
|
| Pyridones | 1 | 2020 | 40 | 0.170 |
Why?
|
| Fats | 1 | 2019 | 8 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 507 | 0.170 |
Why?
|
| Body Composition | 1 | 2020 | 119 | 0.170 |
Why?
|
| Insulin Resistance | 3 | 2019 | 241 | 0.170 |
Why?
|
| Antibody Affinity | 1 | 2019 | 26 | 0.160 |
Why?
|
| Case-Control Studies | 2 | 2013 | 1553 | 0.160 |
Why?
|
| Piperazines | 1 | 2020 | 206 | 0.160 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2021 | 277 | 0.160 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 186 | 0.160 |
Why?
|
| Antibodies, Viral | 1 | 2019 | 110 | 0.150 |
Why?
|
| Bacterial Translocation | 1 | 2018 | 27 | 0.150 |
Why?
|
| Tobacco Use Disorder | 1 | 2022 | 432 | 0.150 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2017 | 9 | 0.140 |
Why?
|
| Immunophenotyping | 1 | 2017 | 110 | 0.140 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2016 | 48 | 0.140 |
Why?
|
| Lopinavir | 1 | 2016 | 18 | 0.140 |
Why?
|
| Ritonavir | 1 | 2016 | 18 | 0.140 |
Why?
|
| Infant, Newborn | 2 | 2019 | 2455 | 0.130 |
Why?
|
| Premature Birth | 1 | 2018 | 150 | 0.130 |
Why?
|
| Incidence | 2 | 2018 | 1603 | 0.130 |
Why?
|
| Vaccines, Inactivated | 1 | 2014 | 3 | 0.120 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2014 | 8 | 0.120 |
Why?
|
| Liver | 1 | 2020 | 1118 | 0.120 |
Why?
|
| Cathelicidins | 1 | 2014 | 11 | 0.120 |
Why?
|
| Middle Aged | 5 | 2021 | 21147 | 0.120 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2014 | 10 | 0.120 |
Why?
|
| Coronary Disease | 1 | 2016 | 358 | 0.120 |
Why?
|
| Atherosclerosis | 1 | 2016 | 204 | 0.120 |
Why?
|
| Protein Binding | 1 | 2017 | 1027 | 0.110 |
Why?
|
| Cholesterol, LDL | 1 | 2014 | 161 | 0.110 |
Why?
|
| Fetal Blood | 1 | 2013 | 131 | 0.110 |
Why?
|
| Metabolic Diseases | 1 | 2013 | 37 | 0.110 |
Why?
|
| Sunlight | 1 | 2012 | 59 | 0.100 |
Why?
|
| RNA, Viral | 1 | 2012 | 93 | 0.100 |
Why?
|
| Obesity | 1 | 2019 | 1076 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2014 | 737 | 0.100 |
Why?
|
| Tobacco Use | 2 | 2022 | 98 | 0.100 |
Why?
|
| Tobacco | 2 | 2022 | 161 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2017 | 1451 | 0.090 |
Why?
|
| Disease Progression | 1 | 2014 | 1038 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1054 | 0.090 |
Why?
|
| Motor Activity | 1 | 2012 | 621 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2012 | 867 | 0.080 |
Why?
|
| Prevalence | 1 | 2013 | 1619 | 0.080 |
Why?
|
| United States | 3 | 2018 | 7367 | 0.080 |
Why?
|
| Quality of Life | 1 | 2016 | 1515 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 931 | 0.060 |
Why?
|
| Varenicline | 1 | 2022 | 98 | 0.050 |
Why?
|
| Nicotinic Agonists | 1 | 2022 | 111 | 0.050 |
Why?
|
| Adipogenesis | 1 | 2019 | 17 | 0.040 |
Why?
|
| Adipocytes | 1 | 2019 | 88 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 1342 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2019 | 150 | 0.040 |
Why?
|
| Progesterone | 1 | 2018 | 115 | 0.040 |
Why?
|
| Risk | 1 | 2018 | 563 | 0.030 |
Why?
|
| Ethiopia | 1 | 2016 | 16 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 455 | 0.030 |
Why?
|
| Georgia | 1 | 2015 | 161 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1266 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2016 | 115 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2016 | 111 | 0.030 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2014 | 10 | 0.030 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2014 | 13 | 0.030 |
Why?
|
| Lipids | 1 | 2016 | 298 | 0.030 |
Why?
|
| Hepatitis C | 1 | 2015 | 114 | 0.030 |
Why?
|
| Health Services Research | 1 | 2015 | 209 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2015 | 287 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 504 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 772 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2015 | 7277 | 0.010 |
Why?
|